A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.

Knapman, Alisa

A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro. [electronic resource] - British journal of pharmacology May 2015 - 2258-72 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1476-5381

10.1111/bph.13047 doi


Adenylyl Cyclase Inhibitors--pharmacology
Adenylyl Cyclases--metabolism
Analgesics, Opioid--pharmacology
Animals
Buprenorphine--pharmacology
CHO Cells
Cricetulus
Dose-Response Relationship, Drug
Enkephalin, Ala(2)-MePhe(4)-Gly(5)---pharmacology
Fentanyl--pharmacology
G Protein-Coupled Inwardly-Rectifying Potassium Channels--agonists
Genotype
Humans
Ion Channel Gating--drug effects
Mitogen-Activated Protein Kinase 1--metabolism
Mitogen-Activated Protein Kinase 3--metabolism
Morphine--pharmacology
Phenotype
Phosphorylation
Polymorphism, Single Nucleotide
Receptors, Opioid, mu--agonists
Signal Transduction--drug effects
Time Factors
Transfection
beta-Endorphin--pharmacology